To totally deplete activity for Ezh2 in NSCLC cells, we combined simultaneous dox and GSK343 treatment, and this resulted in the synergistic inhibition of cell growth (Fig. 1 E). Here, EZH2 is linked to non-small cell lung carcinoma.